Novavax: differenze tra le versioni

Versione delle 00:11, 4 dic 2021

Versione delle 00:18, 4 dic 2021

Riga 35:

==Coadiuvanti dei vaccini==

Novavax sviluppa anche [[Adiuvante (immunologia)|adiuvanti]] immunologici brevettati a base di [[saponina]] immuno-stimolanti presso una consociata svedese interamente controllata, la Novavax AB. Uno di questi, Matrix-M, <ref>{{cita web|lingua=en|url= https://www.bbc.com/future/article/20211201-what-will-the-next-generation-of-covid-19-vaccines-be-like|titolo= What will tomorrow's Covid-19 vaccines be like?}}</ref><ref>{{Cite journal|doi=10.1007/s12026-018-8991-x|title=Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice|year=2018|last1=Magnusson|first1=Sofia E.|last2=Altenburg|first2=Arwen F.|last3=Bengtsson|first3=Karin Lövgren|last4=Bosman|first4=Fons|last5=De Vries|first5=Rory D.|last6=Rimmelzwaan|first6=Guus F.|last7=Stertman|first7=Linda|journal=Immunologic Research|volume=66|issue=2|pages=224–233|pmid=29594879|pmc=5899102}}</ref> è utilizzato nel vaccino di Novavax per il COVID-19, il Nuvaxovid. <ref>{{Cite web|title=Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate {{!}} Novavax Inc. - IR Site|url=https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-1-data-its-covid-19-vaccine|access-date=2021-06-19|website=ir.novavax.com|language=en}}</ref><ref name=KHN>Sarah Jane Tribble and Rachana Pradhan. [https://khn.org/news/article/covid-vaccine-novavax-vaccination-effort-from-zero-to-not-quite-warp-speed/ Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed] Kaiser Health News, Kaiser Family Foundation, July 19, 2021.</ref>

==Note==